METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Clinical trials for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough pancreatic cancer? early trial tests combo therapy
Disease control Not yet recruitingThis is an early safety study for people with advanced pancreatic cancer that has spread and stopped responding to standard chemotherapy. It will test a combination of two drugs, cosibelimab and balixafortide, to find the safest dose and see if the treatment is tolerable. The mai…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Arsen Osipov • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC
-
Breakthrough trial aims to extend lives of pancreatic cancer patients
Disease control Not yet recruitingThis study is testing whether adding an experimental drug called telisotuzumab adizutecan to standard chemotherapy works better for people with advanced pancreatic cancer that has spread. About 900 patients worldwide will receive either the new combination or standard treatment a…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New Four-Drug attack on deadly pancreatic cancer enters final testing
Disease control Not yet recruitingThis large, late-stage study is testing whether adding two new drugs (chiauranib and toripalimab) to standard chemotherapy works better for people with advanced pancreatic cancer that has spread. About 558 adults who have not yet received treatment for their metastatic cancer wil…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Chipscreen Biosciences, Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New hope for tough pancreatic cancer: trial tests Immune-Boosting combo
Disease control Not yet recruitingThis study is testing a new drug called ONT01 combined with standard chemotherapy (gemcitabine and nab-paclitaxel) for people with metastatic pancreatic cancer that has worsened after their first treatment. The goal is to see if this combination can better control the cancer by c…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC